FDA Awards Fast Track Designation to aTyr’s Resolaris

aTyr Pharma has won fast track designation for Resolaris to treat limb girdle muscular dystrophy.

The FDA also lifted its partial clinical hold on a dosing limit for Resolaris in clinical trials.

At this time, study results showed that 78 percent of the Resolaris patients in the trial experienced an increase in muscle function at 14 weeks.